Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/53381

言語	英語
著者	Shigematsu Takashi Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama-City, Wakayama, 641-8509, Japan Muraoka Ryoichi Data Science Group, Clinical Development Department, EA Pharma Co., Ltd, Tokyo, Japan 杉本利嗣 Nishizawa Yoshiki Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
主題	Chronic kidney disease (CKD); Bone disease; Osteoporosis; Biomarkers; Calcium; Treatment
掲載誌名	BMC NEPHROLOGY
巻	18
ISSN	1471-2369
発行日	2017-02-15
DOI	10.1186/s12882-017-0478-9
PubMed ID	28201994
出版者	BIOMED CENTRAL LTD
資料タイプ	学術雑誌論文
部局	医学部
備考	This study was supported by the Joint Development Program of EA Pharma Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Funding for writing/editorial support was provided by EA Pharma Co., Ltd.